Who we are

Digistain wants to prevent every breast cancer patient from unnecessary chemotherapy by offering rapid personalised cancer treatment decision-making for patients and physicians.

Digistain is a cancer diagnostics company combining advanced and validated techniques with machine learning methods to deliver radically faster breast cancer treatment decision-making data for physicians and patients, reducing informed actionable treatment decision times (time to treatment) from months and weeks to days and hours – all at a dramatically lower cost.

Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.

The company is rethinking traditional approaches to cancer risk profiling by using long proven chemical analytics techniques, but for the first time applying that technology specifically to breast cancer risk scoring and augmenting the process using machine learning. Digistain had developed an MHRA approved world-class digital technology created by a team of leading cancer researchers which has been successfully trailed in prominent cancer centres of excellence.  Digistain’s approach personalises critical care decisions and predicts individual patient outcomes which can lead to the avoidance of unnecessary chemotherapy treatment.  

Digistain’s point-of-care device has undergone several clinical trials, which have shown that it is able to generate an objective diagnostic score with prognostic ability.
Based on 15 years of research and development by prominent physicists and cancer researchers.
Using mid-infrared imaging to map the nuclear-to-cytoplasmic ratio (NCR)
Digistain cancer diagnostics

The Team

Digistain cancer diagnostics
Dr Hemmel Amrania

During 10 years employment as a physicist during which Amrania spear-headed the research and development of Digistain as cancer diagnostic device from its infancy in the lab, through designing and conducting clinical trials to commissioning a prototype in a cancer hospital whilst filing two diagnostic technology patents along the way.

Digistain cancer diagnostics
Prof Chris Phillips

Phillips travelled in the developing world and worked for the BBC before taking up a faculty position in the Physics department of Imperial College London in 1985, at the age of 27. He was a visiting researcher at the Quantum Institute, University of California, Santa Barbara in 1997-98. He was elected a Fellow of the Institute of Physics in 2006 and served as Dean of the Faculty of Natural Sciences at Imperial College London, 2008-11.

Supported by:

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.